Purinergic mechanosensory transduction and visceral pain by Burnstock, G
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Molecular Pain
Open Access Review
Purinergic mechanosensory transduction and visceral pain
Geoffrey Burnstock
Address: Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
Email: Geoffrey Burnstock - g.burnstock@ucl.ac.uk
Abstract
In this review, evidence is presented to support the hypothesis that mechanosensory transduction
occurs in tubes and sacs and can initiate visceral pain. Experimental evidence for this mechanism in
urinary bladder, ureter, gut, lung, uterus, tooth-pulp and tongue is reviewed. Potential therapeutic
strategies are considered for the treatment of visceral pain in such conditions as renal colic,
interstitial cystitis and inflammatory bowel disease by agents that interfere with mechanosensory
transduction in the organs considered, including P2X3 and P2X2/3 receptor antagonists that are
orally bioavailable and stable in vivo and agents that inhibit or enhance ATP release and breakdown.
Introduction
Visceral pain is one of the most common forms of pain
associated with pathological conditions like renal colic,
dyspepsia, inflammatory bowel disease (IBD), angina,
dysmenorrhoea and interstitial cystitis. While it is gener-
ally accepted that IBD is associated with pain (see [1,2])
there are reports that in some patients with IBD, there is
hyposensitivity. P2X3 (homomultimer) and P2X2/3 (heter-
omultimer) receptors were cloned and shown to be
largely located on small nociceptive sensory neurons in
the dorsal root ganglia (DRG) in 1995 [3,4]. A schematic
showing the initiation of nociception by ATP on primary
afferent fibres in the periphery and purinergic relay path-
ways in the spinal cord are shown in Figure 1.
A hypothesis was proposed that purinergic mechanosen-
sory transduction occurred in visceral tubes and sacs,
including ureter, bladder and gut, where ATP released
from epithelial cells during distension acted on P2X3
homomeric and P2X2/3 heteromeric receptors on subepi-
thelial sensory nerves initiating impulses in sensory path-
ways to pain centres in the central nervous system (CNS)
[5] (Figure 2a). Evidence supporting this hypothesis in
various organs is reviewed below.
Urinary bladder
Early evidence for ATP release from rabbit urinary bladder
epithelial cells by hydrostatic pressure changes was pre-
sented by Ferguson et al. [6], who speculated about this
being the basis of a sensory mechanism. Prolonged expo-
sure to a desensitizing concentration of α,β-methylene
ATP (α,β-meATP) significantly reduced the activity of
mechanosensitive pelvic nerve afferents in an in vitro
model of rat urinary bladder [7]. Later, it was shown that
mice lacking the P2X3 receptor exhibited reduced inflam-
matory pain and marked urinary bladder hyporeflexia
with reduced voiding frequency and increased voiding
volume, suggesting that P2X3 receptors are involved in
mechanosensory transduction underlying both inflam-
matory pain and physiological voiding reflexes [8]. Subse-
quently, using P2X2  knockout mice and P2X2/P2X3
double knockout mice, a role for the P2X2 subtype was
shown to be involved in mediating the sensory effect of
ATP [9]. In a systematic study of purinergic mechanosen-
sory transduction in the mouse urinary bladder, ATP was
shown to be released from urothelial cells during disten-
sion, and activity initiated in pelvic sensory nerves was
mimicked by ATP and α,β-meATP and attenuated by P2X3
antagonists as well as in P2X3 knockout mice; P2X3 recep-
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tors were localized on suburothelial sensory nerve fibres
[10]. It appears that the bladder sensory DRG neurons,
projecting via pelvic nerves, express predominantly P2X2/
3 heteromultimer receptors [11].
Sensory information from the urinary bladder is conveyed
by both lumbar splanchnic (LSN) and sacral pelvic (PN)
nerves to the spinal cord. A study comparing the mech-
anosensitive properties of single afferent fibres in these
two pathways showed that both low and high threshold
stretch-sensitive afferents were present in both pathways
[12]. Single unit analysis of sensory fibres in the mouse
urinary bladder revealed both low- and high-threshold
fibres sensitive to ATP contributing to physiological (non-
nociceptive) and nociceptive mechanosensory transduc-
tion, respectively [13]. It was also shown that purinergic
agonists increase the excitability of afferent fibres to dis-
tension. The roles of ATP released from urothelial cells
and suburothelial myofibroblasts on various bladder
functions have been considered at length in several
reviews [14,15], and evidence presented that urothelial-
released ATP alters afferent nerve excitability [16]. Amilo-
ride, a blocker of epithelial Na+ channels, has been shown
to suppress ATP release from cultured urothelial cells by a
hypotonic (mechanical) stimulus [17] or by stretch of
intact bladder [18]. Raising the intracellular Ca2+ concen-
tration inhibits stimulation-evoked ATP release from
urothelial cells [19].
ATP given intravesically stimulates the micturition reflex
in awake freely moving rats, probably by stimulating sub-
urothelial C-fibres, although other mediators are likely to
be involved [20]. Studies of resiniferatoxin desensitiza-
tion of capsaicin-sensitive afferents on detrusor overactiv-
ity induced by intravesicle ATP in conscious rats
supported the view that increased extracellular ATP has a
role in mechanosensory transduction and that ATP-
induced facilitation of the micturition reflex is mediated,
at least partly, by nerves other than capsaicin-sensitive
afferents [8,21]. ATP has also been shown to induce a
dose-dependent hypereflexia in conscious and anesthe-
tized mice, largely via capsaicin-sensitive C-fibres; these
effects were dose-dependently inhibited by pyridoxal-
phosphate-6-azonphenyl-2',4'-disulfonic acid (PPADS)
and 2',3'-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) [22]
(Figure 2a). P2X1 and P2X3 receptors play a fundamental
role in the micturition reflex in female urethane-anesthe-
tized rats; P2X3 receptor blockade by phenol red raised the
pressure and volume thresholds for the reflex, while P2X1
receptor blockade diminished motor activity associated
with voiding [23]. In TRPV1 receptor knock-out mice,
release of ATP is significantly depressed [24] and afferent
sensitivity to distension is attenuated, especially those
effects mediated by low threshold fibres related to the
micturition reflex, rather than the high threshold nocice-
ptive fibres [25].
Four functionally distinct populations of bladder sensory
neurons were identified with electrophysiological record-
ings when guinea-pig bladder was subjected to a range of
Hypothetical schematic of the roles of purine nucleotides  and nucleosides in pain pathways Figure 1
Hypothetical schematic of the roles of purine nucle-
otides and nucleosides in pain pathways. At sensory 
nerve terminals in the periphery, P2X3 and P2X2/3 receptors 
have been identified as the principal P2X purinoceptors 
present, although recent studies have also shown expression 
of P2Y1 and possibly P2Y2 receptors on a subpopulation of 
P2X3 receptor-immunopositive fibers. Other known P2X 
purinoceptor subtypes (1--7) are also expressed at low levels 
in dorsal root ganglia. Although less potent than ATP, adeno-
sine (AD) also appears to act on sensory terminals, probably 
directly via P1(A2) purinoceptors; however, it also acts syn-
ergistically (broken black line) to potentiate P2X2/3 receptor 
activation, which also may be true for 5-hydroxytryptamine, 
capsaicin, and protons. At synapses in sensory pathways in 
the CNS, ATP appears to act postsynaptically via P2X2, P2X4 
and/or P2X6 purinoceptor subtypes, perhaps as heteromul-
timers, and after breakdown to adenosine, it acts as a pre-
junctional inhibitor of transmission via P1(A2) purinoceptors. 
P2X3 receptors on the central projections of primary afferent 
neurons in lamina II of the dorsal horn mediate facilitation of 
glutamate and probably also ATP release. Sources of ATP 
acting on P2X3 and P2X2/3 receptors on sensory terminals 
include sympathetic nerves as well as endothelial, Merkel, 
and tumor cells. Yellow dots, molecules of ATP; red dots, 
molecules of adenosine. (Reproduced from [114] and modi-
fied from [105], used with permission from the American 
Physiological Society.)Molecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
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mechanical stimuli (stretch, von Frey hair stroking and
focal compression of receptive fields) and chemical stim-
uli (α,β-methylene ATP and capsaicin) [26]. Four differ-
ent major classes of extrinsic sensory C fibres have been
identified in the guinea-pig bladder: one mediates muscle
mechanoresponses and was unaffected by removal of the
urothelium; another was activated by stretch and α,β-
meATP and was reduced by urothelial removal; the third
were stretch insensitive, but could be activated by mucosal
stroking with von Frey hairs or α,β-meATP and reduced by
urothelium removal; while the fourth class were stretch
insensitive, but could be weakly activated by mucosal
stroking, but not by α,β-meATP [26].
Despite the compelling evidence in support of purinergic
mechanosensory transduction from several independent
laboratories (including stimulation by α,β-meATP of 2 of
the 4 sensory afferents classes described by Zagorodnyuk
et al. [26]), a recent paper from this group claims that
urothelial release of ATP and stimulation of sensory fibres
is not involved in mechanosensory transduction in the
bladder, but that benzamil-sensitive stretch-activated ion
channels are more likely to be involved [27]. Further
experiments will hopefully resolve this issue.
In rats with detrusor overactivity induced by bladder out-
let obstruction, there is an increase in expression of mus-
carinic receptors and an increase, but to a smaller extent,
of P2X3 receptor immunostaining [28]. Cyclophospha-
mide-induced bladder inflammation (a model for inter-
stitial cystitis), sensitizes and enhances P2X3 and P2X2/3
receptor function in rat bladder sensory neurons [29].
Botulinum toxin A, which has antinociceptive effects in
treating interstitial cystitis, inhibits distension-mediated
urothelial release of ATP in conditions of bladder inflam-
mation [30] as well as ATP release as a cotransmitter with
acetylcholine from parasympathetic nerves [31].
In summary, there is now strong evidence from several
different laboratories that ATP is released from urothelial
cells during distension of the bladder wall. The ATP then
activates sensory nerve endings beneath the urothelium,
via P2X3 and P2X2/3 receptors, that leads, via low thresh-
old fibres, to modulation of the voiding reflex and via
high threshold fibres to reach pain centres in the CNS.
Ureter
The uroteric colic that is induced by the passage of a kid-
ney stone causes severe pain. Immunostaining of P2X3
receptors in sensory nerves in the subepithelial region was
reported [32]. Multifibre recordings of ureter afferent
nerves were made using a guinea pig preparation perfused
in vitro [33]. Distension of the guinea-pig ureter increased
spike discharge in sensory neurons, which was mimicked
by ATP and reduced by ATP antagonists [33] (Figure 3a).
The afferent responses consisted of both fast and slow
components. The P2 receptor antagonists TNP-ATP and
PPADS reduced distension-induced afferent activity (Fig-
ure 3b) and blocked the rapid and reduced the slower
response to ATP, while the remaining responses were
blocked by the selective A1  receptor antagonist 8-
cyclopentyl-1,3-dipropylxanthine. The ecto-ATPase inhib-
itor (ARL-67156) produced an increase in base-line and
distension-induced sensory discharge.
Knight et al. [34] found that distending the perfused
guinea-pig ureter at pressures from 20-700 cm H2O
caused a pressure-dependent release of ATP from urothe-
lial cells, approximately 10 times the basal release levels.
The ATP release was abolished by removal of the urothe-
lium and scanning electronmicroscopy confirmed an
intact urothelium after distension. ATP was not released
due to activation of stretch-activated channels since gado-
linium failed to affect ATP release, nor did glibenclamide,
known to inhibit ATP-binding cassette proteins. However,
both monensin and brefeldin A, which interfere with
vesicular formation and trafficking, inhibited distension-
evoked ATP release, which was Ca2+-dependent, indicat-
ing that ATP release from ureter urothelium might be
largely mediated by vesicular exocytosis. In a recent study
in our laboratory, experiments have been carried out to
show that ATP is released from the human ureter upon
distension (Figure 4a) and that human ureteric subu-
rothelial sensory nerves express P2X3 receptors [35].
A. Schematic representation of hypothesis for purinergic mechanosensory transduction in tubes (e.g., ureter, vagina, salivary  and bile ducts, gut) and sacs (e.g., urinary and gall bladders, lung) Figure 2 (see previous page)
A. Schematic representation of hypothesis for purinergic mechanosensory transduction in tubes (e.g., ureter, 
vagina, salivary and bile ducts, gut) and sacs (e.g., urinary and gall bladders, lung). It is proposed that distension 
leads to release of ATP from epithelium lining the tube or sac, which then acts on P2X3 and/or P2X2/3 receptors on subepithe-
lial sensory nerves to convey sensory/nociceptive information to the CNS. (Reproduced from [5], with permission from Black-
well.) B. schematic of a novel hypothesis about purinergic mechanosensory transduction in the gut. It is proposed that ATP 
released from mucosal epithelial cells during moderate distension acts preferentially on P2X3 and/or P2X2/3 receptors on low-
threshold subepithelial intrinsic sensory nerve fibers (labelled with calbindin) to modulate peristaltic reflexes. ATP released 
during extreme (colic) distension also acts on P2X3 and/or P2X2/3 receptors on high-threshold extrinsic sensory nerve fibers 
[labelled with isolectin B4 (IB4) or are peptidergic] that send messages via the dorsal root ganglia (DRG) to pain centres in the 
CNS. (Reproduced and modified from [115], published by John Wiley and Sons, Inc.)Molecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
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A. Spontaneous and distension-induced activity in ureter afferent fibres Figure 3
A. Spontaneous and distension-induced activity in ureter afferent fibres. Multifibre afferent responses to rapid dis-
tension. Note that background afferent activity occurs in bursts and that ureter distension results in an initial burst of discharge 
(circle) followed by a phase of maintained activity (bar). B. ATP can sensitise ureter afferent fibres. An example representative 
of distension-induced afferent activity before and following intraluminal application of increasing concentrations of ATP. c. 
TNP-ATP inhibits distension-induced afferent activity. A multifibre recording to show distension-induced afferent activity in 
control and in the presence of TNP-ATP. (Reproduced from [33], with permission of Elsevier.)Molecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
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A. ATP concentration ([ATP]) in perfusate immediately before and after distension of the human ureter, grouped in pressure  ranges Figure 4
A. ATP concentration ([ATP]) in perfusate immediately before and after distension of the human ureter, 
grouped in pressure ranges. The mean [ATP] after distension is significantly greater than before distension in each pressure 
range P < 0.01; n = 7, error bars represent s.e.m. (Reproduced from [35], with permission from Springer.) B. ATP concentra-
tion in luminal fluid samples from normal and inflamed rat colorectum during distension. Values are means ± SE. (Reproduced 
from [67] and used with permission from the American Physiological Society.)Molecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
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The release of ATP only occurred above a threshold of 25-
30 com H2O. This is similar to the uroteric pressure
threshold for pain measured by Risholm [36]. In a recent
review of the physiology and pharmacology of the human
ureter, it was suggested that purinergic receptors might be
target analgesics for the treatment of ureteral colicky pain
and that an additional advantage might be facilitating
spontaneous ureteral stone passage [37].
Gut
A hypothesis was proposed suggesting that purinergic
mechanosensory transduction in the gut initiated both
physiological reflex modulation of peristalsis via intrinsic
sensory fibres and nociception via extrinsic sensory fibres
[38,39] (Figure 2b). Evidence in support of this hypothe-
sis was obtained from a rat pelvic sensory nerve-colorectal
preparation [40]. Distension of the colorectum led to
pressure-dependent increase in release of ATP from
mucosal epithelial cells (Figure 4b) and also evoked pelvic
nerve excitation. This excitation was mimicked by applica-
tion of ATP and α,β-meATP and attenuated by the selec-
tive P2X3 and P2X2/3 antagonist TNP-ATP and by PPADS.
The sensory discharge was potentiated by ARL-67156, an
ATPase inhibitor. Single fibres analysis showed that high-
threshold fibres were particularly affected by α,β-meATP.
In addition to release of ATP from mucosal epithelial cells
in the rat gut in response to distension (see [40]), ATP has
also been shown to be released from human intestinal
epithelial cells in response to osmotic swelling [41,42].
The interactions of ATP with other mediators that activate
pelvic afferent fibres in the rat colorectum, including cap-
saicin, 5-hydroxytryptamine (5-HT), bradykinin, prostag-
landins and substance P (SP), have been described
[43,44]. In addition, TRPV1 channels are activated and
sensitised by ATP that is released during distension
[45,46], especially in pathological states such as colitis
[47-49]. Carvacral, an agonist for TRPV3 channels, caused
increased ATP release from colonic epithelial cells [50]
and TRPV4 channels have also been shown to mediate
stretch-release of ATP from urothelial cells [51]. LSN and
PN nerves convey different mechanosensory information
from the colon to the spinal cord. Forty percent of LSN
afferents responded to α,β-meATP compared with only
7% of PN afferents [52].
Purinergic mechanosensory transduction has been
described in other regions of the gastrointestinal tract. For
instance, α,β-meATP was shown to stimulate mechano-
sensitive mucosal and tension receptors in mouse stom-
ach and oesophagus leading to activity in vagal afferent
nerves [53]. The sensitizing effects of P2X3 receptor ago-
nists on mechanosensory function are induced in
oesophagitis [54]. Vagal nodose (placode-derived) nocic-
eptive fibres in guinea-pig oesophagus are exclusively C-
fibres sensitive to P2X3  receptor agonists and rarely
express SP, while jugular (neural crest-derived) nocicep-
tive fibres include both A- and C-fibres and are insensitive
to P2X3 agonists and mostly express SP [55]. Adenosine
has been claimed to activate a subset of nociceptive vagal
sensory nerves in guinea-pig oesophagus [56]. Visceral
hypersensitivity may play a role in the pathogenesis of
functional chest pain claimed to be of oesophageal origin.
Theophylline ameliorated chest pain in 7 out of 8 patients
in a clinical trial, perhaps by reducing adenosine-medi-
ated nociception [57]. Purinergic mechanosensory trans-
duction has also been implicated in reflex control of
intestinal secretion, whereby ATP released from mucosal
epithelial cells acts on P2Y1 receptors on enterochromaf-
fin cells to release 5-HT (and ATP, which is stored and co-
released with 5-HT from enterochromaffin cells [58]),
which leads to regulation of secretion either directly or via
intrinsic reflex activity [59].
Subepithelial fibroblasts in intestinal villi are highly sen-
sitive to mechanical stimulation and release ATP during
touch or stretch and probably act as mechanosensors [60].
The ATP released activates P2Y1 receptors on surrounding
cells, which leads to intercellular propagation of Ca2+
waves and contractions in networks of subepithelial
fibroblasts and a signal to sensory nerve terminals in the
villi [61]. Intrinsic enteric sensory nerves express P2X3 and
P2X2/3 receptors [62-66]. In P2X2 or P2X3 knock-out mice,
intraluminal pressure-induced peristalsis is inhibited
[65,66].
ATP release and P2X3 and P2X2/3 receptor-mediated noci-
ceptive sensory nerve responses were enhanced in a model
of colitis consisting of administration to adult rats of an
intrarectal enema of 30% trinitro benzene sulfonic acid in
ethanol at a dose of 80 mg/kg body weight [67]. An
increase in the number of DRG neurons supplying the
colorectum expressing P2X3 receptors was also claimed
and there was also a substantial increase in release of ATP
with distension (Figure 4b). The excitability of visceral
afferent nerves is enhanced following injury or ischemia
and during inflammation, for example, in irritable bowel
syndrome (IBS) [68]. Under these conditions, substances
are released from various sources that often act synergisti-
cally to cause sensitization of afferent nerves to mechani-
cal or chemical stimuli. Receptors to these substances
(including ATP) represent potential targets for drug treat-
ment aimed at attenuating the inappropriate visceral sen-
sation and subsequent reflex activities that underlie
abnormal bowel function and visceral pain (see [69,70]).
Chronic functional visceral hyperalgesia induced in a rat
model for IBS, induced by colonic injection of 0.5% acetic
acid, is associated with potentiation of ATP-evoked
responses and an enhanced expression of P2X3 receptors
in colon-specific sensory neurons [71]. In addition, activa-
tion of spinal A1 receptors with adenosine, followingMolecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
Page 8 of 12
(page number not for citation purposes)
breakdown of ATP, has been shown to modulate visceral
hyperalgesia [72].
Non-erosive reflux disease shows the classic symptoms of
gastro-oesophageal reflux, but in the absence of oesopha-
geal mucosal injury. Visceral hypersensitivity plays an
important role in the pathology of this disease [73]. ATP
has been found to sensitise vagal afferents to mechanical
stimuli in the ferret oesophagus [54] and the protein
expression of P2X3 receptors is increased in nodose and
DRG with chronic oesophageal acid exposure in a rat
model [74].
Lung
In the lung, pulmonary neuroepithelial bodies (NEBs)
and more recently subepithelial receptor-like endings
associated with smooth muscle (SMARs) [75] have been
shown to serve as sensory organs in the lung, and P2X3and
P2X2/3  receptors are expressed on a subpopulation of
vagal sensory fibres that supply NEBs and SMARs with
their origin in the nodose ganglia. Quinacrine staining of
NEBs indicates the presence of high concentrations of ATP
in their secretory vesicles, and it has been suggested that
ATP is released in response to both mechanical stimula-
tion during high-pressure ventilation and during hypoxia
[76]. NEBs are oxygen sensors especially in early develop-
ment, before the carotid system has matured [77]. In a
study of bronchopulmonary afferent nerve activity of a
mouse isolated perfused nerve-lung preparation, it was
found that C fibres could be subdivided into two groups:
fibres that conduct action potentials at < 0.7 ms-1 and are
responsive to capsaicin, bradykinin and ATP; and fibres
that conduct action potentials on an average of 0.9 ms-1
and respond vigorously to ATP, but not to capsaicin or
bradykinin [78]. Both the TRPV1 receptor and P2X recep-
tors mediate the sensory transduction of pulmonary reac-
tive oxygen species, especially H2O2  and OH, by
capsaicin-sensitive vagal lung afferent fibres [79].
Vagal C-fibres innervating the pulmonary system are
derived from cell bodies situated in two distinct vagal sen-
sory ganglia: the jugular (superior) ganglion neurons
project fibres to the extrapulmonary airways (larynx, tra-
chea, bronchus) and the lung parenchymal tissue, while
the nodose (inferior) neurons innervate primarily struc-
tures within the lungs. Nerve terminals in the lungs from
both jugular and nodose ganglia responded to capsaicin
and bradykinin, but only the nodose C-fibres responded
to α,β-meATP. Vagal afferent purinergic signaling may be
involved in the hyperactivity associated with asthma and
chronic obstructive pulmonary disease [80]. Th1 and Th2
cytokines reciprocally regulate P2X7  receptor function,
suggesting a role for P2X7 receptors in pulmonary dis-
eases, particularly lung hypersensitivity associated with
chronic inflammatory responses [81].
Uterus
It has been hypothesised that tissue stress or damage in
the uterine cervix during late pregnancy and parturition
leads to ATP release and sensory signalling via P2X recep-
tors [82]. In support of this proposal, these authors have
shown P2X3 receptor immunoreactivity in axons in the
cervix, in small and medium sized neurons in L6/S1 DRG
and in lamina II of the L6/S1 spinal cord segments and
increases in P2X3 receptor expression between pregnancy
day 10 and parturition (day 22/23) in the rat cervix,
although not in DRG or spinal cord.
Tooth pulp
P2X3 and P2X2/3 receptors on sensory afferents in tooth
pulp appear to mediate nociception [83-86], perhaps
from ATP released by mechanical distension or inflamma-
tion of odontoblasts. Mustard oil application to the tooth
pulp in anaesthetised rats produced long-lasting central
sensitisation, reflected by increases in neuronal mech-
anoreceptive field size; TNP-ATP reversibly attenuated the
mustard oil sensitisation for more than 15 minutes [87].
Tongue
P2X3 receptors are abundantly present on sensory nerve
terminals in the tongue [88] and ATP and α,β-meATP
have been shown to excite trigeminal lingual nerve termi-
nals in an in vitro preparation of intra-arterially perfused
rat mimicking nociceptive responses to noxious mechani-
cal stimulation and high temperature [89]. A purinergic
mechanosensory transduction mechanism for the initia-
tion of pain was considered. Taste sensations appear to be
mediated both by P2Y1 receptor-activated impulses in sen-
sory fibres in the chorda tympani [90] and by P2X2 and
P2X3 and, perhaps, P2X2/3 receptors [91].
Potential Therapeutic Strategies
The search is on for selective P2X3 and P2X2/3 receptor
antagonists that are orally bioavailable and do not
degrade in vivo for the treatment of pain (see [92-96]).
Table 1: P2X3 and P2X2/3 receptor antagonists
Antagonist P2X3 P2X2/3
Suramin and analogues NF449, NF110 √√
PPADS and derivatives MRS2159 & MRS2257 √√ √
Reactive blue 2 and derivatives TNP-ATP √√
A-317491 (selective) √√√ √√√
Phenol red √√√ √√√
Tetramethylpyrazine √√ -
RO4 (orally bioavailable, stable in vivo) √√ ?
Ip5I √√ √√
βγcarboxymethylene ATP √√ -
βγchlorophosphnomethylene ATP ? √√
? √√
From [93,95,112,113]Molecular Pain 2009, 5:69 http://www.molecularpain.com/content/5/1/69
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Table 1 summarises the drugs widely available. Suramin,
PPADS and Reactive blue 2 have been used as non-selec-
tive antagonists at P2X3 and P2X2/3 receptors on nocicep-
tive sensory nerve endings. PPADS has the advantage that
it associates and dissociates approximately 100 to 10,000
times more slowly than other known antagonists [97].
The trinitrophenyl-substituted nucleotide, TNP-ATP, is a
very potent antagonist at both P2X3 and P2X2/3 receptors.
A-317491 (synthesised by Abbott Laboratories) and com-
pound RO3 (synthesised by Roche Palo Alto) are both
effective P2X3  and P2X2/3  antagonists, the latter being
orally bioavailable and stable in vivo. Antagonism of P2X1
and P2X3 receptors by phenol red has been reported and
tetramethylpyrazine, a traditional Chinese medicine, used
as an analgesic for dysmenorrhoea, was claimed to block
P2X3 receptor signalling [98].
Antisense oligonucleotides have been used to down-regu-
late the P2X3 receptor, and in models of neuropathic (par-
tial sciatic nerve ligation) and inflammatory (complete
Freund's adjuvant pain, inhibition of the development of
mechanical hyperalgesia as well as significant reversal of
established hyperalgesia, were observed within 2 days of
treatment [99-101]. P2X3 antisense oligonucleotides or
antagonists appear to be less effective for treating disco-
genic (lumbar intervertebral disc) than cutaneous tissue
pain [102]. Combined antisense and RNA interference-
mediated treatment for specific inhibition of the recom-
binant rat P2X3 receptor appears to be promising for pain
therapy [103]. P2X3  double-stranded short interfering
RNA relieves chronic neuropathic pain and opens up new
avenues for therapeutic pain strategies in man [104].
While P2X3 and P2X2/3 receptors, expressed in sensory
neurons, were the predominant P2 receptor subtypes first
recognised to be involved in the initiation of nociception
(see [105,106]), it has become apparent more recently
that P2Y receptors are also present [107] and that these are
involved in modulation of pain transmission [108]. P2Y
receptors appear to potentiate pain induced by chemical
or physical stimuli via capsaicin sensitive TRPV1 channels
and it has been proposed that the functional interaction
between P2Y2 receptors and TRPV1 channels in nocicep-
tors could underlie ATP-induced inflammatory pain [45].
P2Y1 receptor-mediated responses also enhance the sensi-
tivity of TRPV1-mediated responses to capsaicin, protons
and temperature in a protein kinase C-dependent manner
[109]. ATP-induced hyperalgesia was abolished in mice
lacking TRPV1 receptors.
It has been claimed that opioids inhibit purinergic nocic-
eption in rat sensory neurons and fibres via a G protein-
dependent mechanism [110]. Cannabinoids act as inhib-
itory modulators of nociceptive responses produced by
P2X2/3 receptors [111].
There are no publications to date describing clinical eval-
uations of P2 receptor antagonists and related purinergic
compounds for the relief of pain, although clinical trials
for some compounds are in progress (see [93,94]). Other
therapeutic approaches to pain are being considered,
including the development of agents that control the
expression of receptors and those that enhance ATP break-
down. Further, while it is now clear that many different
cell types release ATP physiologically in response to
mechanical distortion, hypoxia, and various agents, we
still await clear understanding of the mechanisms that
underlie ATP transport. Hopefully, when this becomes
clearer, agents will be developed that will be able to
inhibit ATP release, another useful way forward as a ther-
apeutic strategy.
Conclusion
Compelling evidence has been presented for the role of
purinergic mechanosensory transduction where ATP,
released from epithelial cells lining the bladder, ureter
and gut during distension, acts on P2X3 and/or P2X2/3
receptors on subepithelial sensory nerve terminals to relay
nociceptive messages via sensory ganglia and spinal cord
to pain centres in the CNS.
Antagonists to P2X3  and P2X2/3  receptors are being
explored to treat visceral pain and the possibilities for
development of agents that inhibit ATP transport from
epithelial cells or enhance ATP breakdown after its release
are discussed.
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